informed that regular daily usage is necessary to maintain control of asthma. However, the patient should be daily. Patients usually experience an improvement in lung function within inhalation of Relvar Ellipta 92/22 micrograms or 184/22 micrograms once is appropriate.

Relvar Ellipta is for symptomatic treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta 2-agonist and inhaled corticosteroid) for the regular treatment of asthma in adults and adolescents aged 12 years and older where current inhaler treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta 2-agonist and inhaled corticosteroid) for the regular treatment of asthma in adults and adolescents aged 12 years and older where current inhaler3,4*

Delivered in an easy to use device that patients prefer to their current inhaler3,4*

The first ICS/LABA combination to deliver continuous 24-hour efficacy2

Relvar Ellipta 92 micrograms/22 micrograms should be considered for adults and adolescents aged 12 years and older for the symptomatic treatment of asthma and COPD. Relvar Ellipta 184 micrograms/22 micrograms, which may provide additional improvement in asthma control on Relvar Ellipta 92/22 micrograms, the dose can be increased to Controlled on Relvar Ellipta 92/22 micrograms, the dose can be increased to

For Athsma: One

Fluticasone furoate/ vilanterol (FF/VI) and FF alone in asthma. ERS. 2013.

For COPD. Relvar Ellipta is for inhalation use only. It should be administered at the same time of the day, each day.

The active ingredient or excipients.

Subjects were treated with Relvar Ellipta (FF/VI) and FF alone in asthma. ERS. 2013.

Inhibitors and sympathomimetic medicinal products (refer to the full prescribing information).

Positive and negative effects of Relvar Ellipta on laboratory and ancillary test findings were evaluated in clinical trials. These findings are summarised in Table 1.

Pharmaceutical Form:

184 micrograms of fluticasone furoate and 22 micrograms of vilanterol

**Active Ingredients:**

**Dosage and Method of Administration:**

**Precautions for Use:**

**Contraindications:**

**Drug Interactions:**

**Local Presentations:**

**Reporting Adverse Events (AEs):**

This medicinal product is subject to additional monitoring. This will allow for the current or previous maintenance inhalers: HandiHaler/ DISKUS/ MDI/ HFA (COPD); DISKUS/ MDI/ HFA (COPD).

Furthermore, in most countries, research funding is apportioned by the number and importance of the grant applicant’s publications. Participation at congresses with oral or poster presentations is also invaluable. But the gold standard remains the original paper written and published in a reputable journal.

**Write a Scientific Paper** is a three day intensive course with formal lectures and interactive sessions. This is an international and unique course that has been successfully held in Malta in 2010, 2011, 2012, 2013 and 2016. Each iteration has led to fine tuning of the contents via feedback from successive attendees.

The course is now being held for the first time in London. This event attempts to facilitate all aspects of paper writing. The course is delivered by highly experienced researchers. The purpose is to impart the lecturers’ collective experience to the delegates in this crucial aspect of career progress. This event is endorsed by the Royal College of Paediatrics & Child Health.

Faculty to date: Prof. Victor Grech, Prof. Charles Savona-Ventura, Prof. Josanne Vassallo, Prof. Jane Somerville and Dr Alessandro Giardini.

The event will be held on 30 January - 1 February, 2017 at the Royal College of Paediatrics & Child Health in London, and has been awarded 18 EU and internationally recognised EACCME accreditation points.

Website: www.ithams.com/wasp/
Facebook: www.facebook.com/events/929892130477166/
This event has been organised by The Institute of Technology, Humanities, the Arts, Medicine and Science and The Malta Institute for Medical Education.

---

**Top Web Reads**

**The Synapse.net**